Clinical Trials · NCT06536023
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 36
- Start date
- Aug 2024
- Locations
- 1 site, China
- Primary endpoint
- Incidence of adverse events and serious adverse events